Reduced Diffusivity along Perivascular Spaces on MR Imaging Associated with Younger Age of First Use and Cognitive Impairment in Recreational Marijuana Users

References

1. 1.↵
   1. Orr JM,
   2. Paschall CJ,
   3. Banich MT

   . Recreational marijuana use impacts white matter integrity and subcortical (but not cortical) morphometry. Neuroimage Clin 2016;12:47–56 doi:10.1016/j.nicl.2016.06.006 pmid:27408790

   CrossRefPubMed
2. 2.↵
   United Nations Office on Drugs. World Drug Report 2022. https://www.unodc.org/unodc/data-and-analysis/world-drug-report-2022.html. Accessed May 3, 2023
3. 3.↵
   1. Blest-Hopley G,
   2. Colizzi M,
   3. Giampietro V, et al

   . Is the adolescent brain at greater vulnerability to the effects of cannabis? A narrative review of the evidence. Front Psychiatry 2020;11:859 doi:10.3389/fpsyt.2020.00859 pmid:33005157

   CrossRefPubMed
4. 4.↵
   1. Jacobus J,
   2. Tapert SF

   . Effects of cannabis on the adolescent brain. Curr Pharm Des 2014;20:2186–93 doi:10.2174/13816128113199990426 pmid:23829363

   CrossRefPubMed
5. 5.↵
   1. Volkow ND,
   2. Baler RD,
   3. Compton WM, et al

   . Adverse health effects of marijuana use. N Engl J Med 2014;370:2219–27 doi:10.1056/NEJMra1402309 pmid:24897085

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Zhang D,
   2. Li X,
   3. Li B

   . Glymphatic system dysfunction in central nervous system diseases and mood disorders. Front Aging Neurosci 2022;14:873697 doi:10.3389/fnagi.2022.873697 pmid:35547631

   CrossRefPubMed
7. 7.↵
   1. Robinson EA,
   2. Gleeson J,
   3. Arun AH, et al

   . Measuring white matter microstructure in 1,457 cannabis users and 1,441 controls: a systematic review of diffusion-weighted MRI studies. Front Neuroimaging 2023;2:1129587 doi:10.3389/fnimg.2023.1129587 pmid:37554654

   CrossRefPubMed
8. 8.↵
   1. Andica C,
   2. Kamagata K,
   3. Takabayashi K, et al

   . Neuroimaging findings related to glymphatic system alterations in older adults with metabolic syndrome. Neurobiol Dis 2023;177:105990 doi:10.1016/j.nbd.2023.105990 pmid:36621631

   CrossRefPubMed
9. 9.↵
   1. Kamagata K,
   2. Andica C,
   3. Takabayashi K, et al

   ; Alzheimer’s Disease Neuroimaging Initiative. Association of MRI indices of glymphatic system with amyloid deposition and cognition in mild cognitive impairment and Alzheimer disease. Neurology 2022;99:e2648–60 doi:10.1212/WNL.0000000000201300 pmid:36123122

   Abstract/FREE Full Text
10. 10.↵
    1. Liff JJ,
    2. Wang M,
    3. Liao Y, et al

    . A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 2012;4:147ra111 doi:10.1126/scitranslmed.3003748 pmid:22896675

    Abstract/FREE Full Text
11. 11.↵
    1. Mestre H,
    2. Mori Y,
    3. Nedergaard M

    . The brain’s glymphatic system: current controversies. Trends Neurosci 2020;43:458–66 doi:10.1016/j.tins.2020.04.003 pmid:32423764

    CrossRefPubMed
12. 12.↵
    1. Kress BT,
    2. Iliff JJ,
    3. Xia M, et al

    . Impairment of paravascular clearance pathways in the aging brain. Ann Neurol 2014;76:845–61 doi:10.1002/ana.24271 pmid:25204284

    CrossRefPubMed
13. 13.↵
    1. Xia M,
    2. Yang L,
    3. Sun G, et al

    . Mechanism of depression as a risk factor in the development of Alzheimer’s disease: the function of AQP4 and the glymphatic system. Psychopharmacology (Berl) 2017;234:365–79 doi:10.1007/s00213-016-4473-9 pmid:27837334

    CrossRefPubMed
14. 14.↵
    1. Sabayan B,
    2. Westendorp RG

    . Neurovascular-glymphatic dysfunction and white matter lesions. Geroscience 2021;43:1635–42 doi:10.1007/s11357-021-00361-x pmid:33851307

    CrossRefPubMed
15. 15.↵
    1. Iliff JJ,
    2. Lee H,
    3. Yu M, et al

    . Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest 2013;123:1299–309 doi:10.1172/JCI67677 pmid:23434588

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Kanda T,
    2. Ishii K,
    3. Kawaguchi H, et al

    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844

    CrossRefPubMed
17. 17.↵
    1. Kamagata K,
    2. Saito Y,
    3. Andica C, et al

    . Noninvasive magnetic resonance imaging measures of glymphatic system activity. J Magn Reson Imaging 2024;59:1476–93 doi:10.1002/jmri.28977 pmid:37655849

    CrossRefPubMed
18. 18.↵
    1. Taoka T,
    2. Masutani Y,
    3. Kawai H, et al

    . Evaluation of glymphatic system activity with the diffusion MR technique: diffusion tensor image analysis along the perivascular space (DTI-ALPS) in Alzheimer’s disease cases. Jpn J Radiol 2017;35:172–78 doi:10.1007/s11604-017-0617-z pmid:28197821

    CrossRefPubMed
19. 19.↵
    1. Zhang W,
    2. Zhou Y,
    3. Wang J, et al

    . Glymphatic clearance function in patients with cerebral small vessel disease. Neuroimage 2021;238:118257 doi:10.1016/j.neuroimage.2021.118257 pmid:34118396

    CrossRefPubMed
20. 20.↵
    1. Steward CE,
    2. Venkatraman VK,
    3. Lui E, et al

    . Assessment of the DTI-ALPS parameter along the perivascular space in older adults at risk of dementia. J Neuroimaging 2021;31:569–78 doi:10.1111/jon.12837 pmid:33556226

    CrossRefPubMed
21. 21.↵
    1. Lee HJ,
    2. Lee DA,
    3. Shin KJ, et al

    . Glymphatic system dysfunction in patients with juvenile myoclonic epilepsy. J Neurol 2022;269:2133–39 doi:10.1007/s00415-021-10799-w pmid:34510256

    CrossRefPubMed
22. 22.↵
    1. Lin LP,
    2. Su S,
    3. Hou W, et al

    . Glymphatic system dysfunction in pediatric acute lymphoblastic leukemia without clinically diagnosed central nervous system infiltration: a novel DTI-ALPS method. Eur Radiol 2023;33:3726–34 doi:10.1007/s00330-023-09473-8 pmid:36882529

    CrossRefPubMed
23. 23.↵
    1. Van Essen DC,
    2. Smith SM,
    3. Barch DM, et al

    ; WU-Minn HCP Consortium. The WU-Minn Human Connectome Project: an overview. Neuroimage 2013;80:62–79 doi:10.1016/j.neuroimage.2013.05.041 pmid:23684880

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Allen JP,
    2. Danoff JS,
    3. Costello MA, et al

    . Lifetime marijuana use and epigenetic age acceleration: a 17-year prospective examination. Drug Alcohol Depend 2022;233:109363 doi:10.1016/j.drugalcdep.2022.109363 pmid:35231715

    CrossRefPubMed
25. 25.↵
    1. Andersson F,
    2. Sundin E,
    3. Magnusson C, et al

    . Prevalence of cannabis use among young adults in Sweden comparing randomized response technique with a traditional survey. Addiction 2023;118:1801–10 doi:10.1111/add.16219 pmid:37132063

    CrossRefPubMed
26. 26.↵
    1. Auer R,
    2. Vittinghoff E,
    3. Yaffe K, et al

    . Association between lifetime marijuana use and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) study. JAMA Intern Med 2016;176:352–61 doi:10.1001/jamainternmed.2015.7841 pmid:26831916

    CrossRefPubMed
27. 27.↵
    1. Wise J

    . Long term marijuana use is linked to impaired verbal memory. BMJ 2016;352:i619 doi:10.1136/bmj.i619 pmid:26838137

    FREE Full Text
28. 28.↵
    1. Albaugh MD,
    2. Ottino-Gonzalez J,
    3. Sidwell A, et al

    ; IMAGEN Consortium. Association of cannabis use during adolescence with neurodevelopment. JAMA Psychiatry 2021;78:1–11 doi:10.1001/jamapsychiatry.2021.1258 pmid:34132750

    CrossRefPubMed
29. 29.↵
    1. Van Essen DC,
    2. Ugurbil K,
    3. Auerbach E, et al

    ; WU-Minn HCP Consortium. The Human Connectome Project: a data acquisition perspective. Neuroimage 2012;62:2222–31 doi:10.1016/j.neuroimage.2012.02.018 pmid:22366334

    CrossRefPubMed
30. 30.↵
    1. Glasser MF,
    2. Sotiropoulos SN,
    3. Wilson JA, et al

    ; WU-Minn HCP Consortium, The minimal preprocessing pipelines for the Human Connectome Project. Neuroimage 2013;80:105–24 doi:10.1016/j.neuroimage.2013.04.127 pmid:23668970

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Taoka T,
    2. Ito R,
    3. Nakamichi R, et al

    . Reproducibility of diffusion tensor image analysis along the perivascular space (DTI-ALPS) for evaluating interstitial fluid diffusivity and glymphatic function: CHanges in Alps index on Multiple conditiON acquIsition eXperiment (CHAMONIX) study. Jpn J Radiol 2022;40:147–58 doi:10.1007/s11604-021-01187-5 pmid:34390452

    CrossRefPubMed
32. 32.↵
    1. Andica C,
    2. Kamagata K,
    3. Hatano T, et al

    . MR biomarkers of degenerative brain disorders derived from diffusion imaging. J Magn Reson Imaging 2020;52:1620–36 doi:10.1002/jmri.27019 pmid:31837086

    CrossRefPubMed
33. 33.↵
    1. Kim JH

    . Multicollinearity and misleading statistical results. Korean J Anesthesiol 2019;72:558–69 doi:10.4097/kja.19087 pmid:31304696

    CrossRefPubMed
34. 34.↵
    1. Renard J,
    2. Krebs MO,
    3. Le Pen G, et al

    . Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Front Neurosci 2014;8:361 doi:10.3389/fnins.2014.00361 pmid:25426017

    CrossRefPubMed
35. 35.↵
    1. Hodges EL,
    2. Ashpole NM

    . Aging circadian rhythms and cannabinoids. Neurobiol Aging 2019;79:110–18 doi:10.1016/j.neurobiolaging.2019.03.008 pmid:31035036

    CrossRefPubMed
36. 36.↵
    1. Jimenez-Blasco D,
    2. Busquets-Garcia A,
    3. Hebert-Chatelain E, et al

    . Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature 2020;583:603–08 doi:10.1038/s41586-020-2470-y pmid:32641832

    CrossRefPubMed
37. 37.↵
    1. Mogensen FL,
    2. Delle C,
    3. Nedergaard M

    . The glymphatic system (en)during inflammation. Int J Mol Sci 2021;22:7491 doi:10.3390/ijms22147491 pmid:34299111

    CrossRefPubMed
38. 38.↵
    1. Morin JG,
    2. Afzali MH,
    3. Bourque J, et al

    . A population-based analysis of the relationship between substance use and adolescent cognitive development. Am J Psychiatry 2019;176:98–106 doi:10.1176/appi.ajp.2018.18020202 pmid:30278790

    CrossRefPubMed
39. 39.↵
    1. Volkow ND,
    2. Swanson JM,
    3. Evins AE, et al

    . Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry 2016;73:292–97 doi:10.1001/jamapsychiatry.2015.3278 pmid:26842658

    CrossRefPubMed
40. 40.↵
    1. Petker T,
    2. Owens MM,
    3. Amlung MT, et al

    . Cannabis involvement and neuropsychological performance: findings from the Human Connectome Project. J Psychiatry Neurosci 2019;44:414–22 doi:10.1503/jpn.180115 pmid:31245962

    Abstract/FREE Full Text
41. 41.↵
    1. Morie KP,
    2. Potenza MN

    . A mini-review of relationships between cannabis use and neural foundations of reward processing, inhibitory control and working memory. Front Psychiatry 2021;12:657371 doi:10.3389/fpsyt.2021.657371 pmid:33967859

    CrossRefPubMed
42. 42.↵
    1. Harrington KD,
    2. Dang C,
    3. Lim YY, et al

    . The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. Intelligence 2018;70:22–29 doi:10.1016/j.intell.2018.07.004

    CrossRef
43. 43.↵
    1. Gilman JM,
    2. Kuster JK,
    3. Lee S, et al

    . Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users. J Neurosci 2014;34:5529–38 doi:10.1523/JNEUROSCI.4745-13.2014 pmid:24741043

    Abstract/FREE Full Text
44. 44.↵
    1. Weiland BJ,
    2. Thayer RE,
    3. Depue BE, et al

    . Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. J Neurosci 2015;35:1505–12 doi:10.1523/JNEUROSCI.2946-14.2015 pmid:25632127

    Abstract/FREE Full Text